Premium
Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides
Author(s) -
Wagner Carston R.,
Iyer Vidhya V.,
McIntee Edward J.
Publication year - 2000
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z
Subject(s) - prodrug , in vivo , nucleotide , pharmacology , medicine , chemistry , biology , biochemistry , microbiology and biotechnology , gene
To overcome the many hurdles preventing the use of antiviral and anticancer nucleosides as therapeutics, the development of a prodrug methodology (i.e., pronucleotide) for the in vivo delivery of nucleotides has been proposed as a solution. The ideal pronucleotide should be non‐toxic, stable in plasma and blood, capable of being i.v. and/or orally dosed, and intracellularly convertible to the corresponding nucleotide. Although this goal has yet to be achieved, many clever and imaginative pronucleotide approaches have been developed, which are likely to be important pharmacological tools. This review will discuss the major advances and future directions of the emerging field of antiviral and anticancer pronucleotide design and development. © 2000 John Wiley & Sons, Inc. Med Res Rev, 20, No. 6, 417–451, 2000